In hospitals, needlestick injury prevention has received decades of legislative attention, engineering investment, and regulatory scrutiny. Hospitals have OSHA mandates, safety committees, annual exposure control plan reviews, and an entire product category - safety-engineered sharps - developed specifically in response to that pressure.

Preclinical animal research has none of that.

Yet the workers who dose rodents in biosafety cabinets, restrain non-human primates for blood draws, and administer experimental compounds across hundreds of animals a day face sharps injury rates that match or exceed those of hospital nurses. And unlike hospital NSIs, which primarily involve bloodborne pathogens from known patients, injuries in preclinical labs often involve substances with no approved human safety profile at all.

This is the sharps safety crisis that no one is talking about.

Between 65% and 93% of animal research and veterinary professionals sustain a needlestick injury over the course of their careers. That is not a risk statistic. That is near-certainty.

The Numbers the Field Isn't Reporting

Direct NSI surveillance data from preclinical research labs is limited. Formal tracking is inconsistent, underreporting is widespread, and the field has not been subject to the same occupational health scrutiny as human healthcare. The closest published benchmarks come from veterinary and laboratory animal settings, where workers perform comparable tasks under comparable conditions - manual restraint, high-volume injection protocols, multi-dose sequencing, and constrained workspaces. The pattern across those settings is consistent and sobering:

• 93% of veterinary technicians reported at least one NSI over their career; 74% had sustained one in the past year alone. [1]
• 75.3% of Australian veterinarians reported at least one sharps exposure within a 12-month period. [2]
• 86.7% of zoo veterinarians report lifetime NSI exposure - some of the highest rates documented across any health-adjacent profession. [3]
• Career NSI prevalence across veterinary and laboratory animal workers ranges from 64% to 87% across multiple independent studies. [3]

These numbers likely understate reality. Studies in human healthcare estimate that 50% to 90% of needlestick injuries go unreported, and researchers believe the same dynamic - injury normalization, time pressure, and a prevailing sense that small sticks are part of the job - is equally or more prevalent in veterinary and research environments. [1]

That means the true annual NSI burden in preclinical research may be substantially higher than any published survey has captured.

Animal Research Is Not Just High-Volume. It Is Uniquely High-Risk.

The injury patterns seen in preclinical labs are not simply a scaled-up version of hospital sharps risk. The environment, the workflow, and the substances involved create a distinct and compounding hazard profile.

Constrained working conditions. Injections in biosafety cabinets, glove boxes, and cage racks require operators to reach into narrow spaces while managing a syringe, often with limited visibility and restricted ability to reposition. There is no analog to this in a typical clinical injection setting.

Manual restraint and unpredictable movement. Many procedures require the operator to simultaneously restrain the animal, control the needle, and maintain sterility. Animals move. Mice kick. Primates resist. Even well-restrained animals can shift during needle insertion or withdrawal in ways that bring a bare needle tip into contact with an unprotected hand.

High-throughput dosing protocols. Pharmacokinetic studies, vaccine trials, and toxicology protocols can require a single technician to perform dozens or hundreds of injections per day. Repetition drives fatigue. Fatigue drives error. And unlike a nurse who may give a dozen injections in a shift, a preclinical tech may perform that volume before lunch.

Recapping is unavoidable - and it is the leading cause of injury. OSHA discourages recapping. Research labs cannot always avoid it. Sterility requirements, multi-dose protocols, and workflow sequencing frequently require a needle to be recapped between animals. Studies show that up to 84% of animal health workers recap regularly, and nearly three-quarters have sustained a recapping-related NSI. Across research and veterinary settings, recapping accounts for more than 25% of all needlestick injuries. [4]

The single most preventable cause of NSIs in preclinical research is recapping. The engineering solution for recapping is one-handed needle handling. Until recently, no device designed specifically for research workflows existed to provide it.

The Exposure Is Not Just a Needle. It Is Whatever Is In the Syringe.

In hospital settings, the primary NSI concern is biological: bloodborne pathogen transmission from a patient source. In preclinical research, the exposure profile is substantially broader - and in many cases, more immediately dangerous.

Workers in animal research labs regularly administer:

• Novel biologics and gene therapy vectors with no established human safety data
• Experimental immunotherapies and viral constructs under active development
• Anesthetics, sedatives, and euthanasia agents with narrow therapeutic windows
• Prostaglandins, chemotherapy compounds, and reproductive hormones
• Vaccines and live-attenuated organisms in early-stage trial conditions
• Radiolabeled compounds and hazardous chemical agents

The consequences of inadvertent self-injection in this context extend well beyond bloodborne pathogen risk. Studies of NSIs in animal health workers find that approximately 16% result in at least one adverse effect. Of those, roughly 4% are classified as severe and systemic - including cardiac disturbances, respiratory changes, and significant tissue necrosis. At least one documented case involved spontaneous abortion following accidental prostaglandin injection, demonstrating that reproductive health is also at stake. [5]

When the syringe contains an investigational compound at a dose calibrated for a 25-gram mouse, a percutaneous human exposure is not a minor incident. It is an exposure event with an unknown risk profile, requiring immediate medical evaluation, potential protocol halts, and regulatory notification.

The Institutional Consequences Are Larger Than the Individual Injury

An NSI in a preclinical lab does not just affect the person who was injured. It affects the protocol they were executing.

Preclinical studies - particularly GLP-compliant studies supporting IND or regulatory submissions - require rigorous adherence to dosing schedules, personnel continuity, and chain-of-custody documentation. When a trained technician is removed from a study for post-exposure evaluation, blood testing, or medical leave, the downstream effects can include:

• Missed dosing windows that compromise data validity
• Substitution of less experienced personnel mid-protocol
• Increased data variability that affects statistical outcomes
• Regulatory reporting obligations depending on the study type and agent involved
• Workers' compensation claims, institutional incident reviews, and protocol audits

In regulated research environments, these disruptions are not administrative inconveniences. They can delay submissions, compromise study integrity, and require costly repeat studies. The research continuity argument for sharps safety in preclinical labs is as strong as the occupational health argument - and in some institutional contexts, it may be more persuasive.

The Safety Devices in This Market Were Not Designed for This Setting

The sharps safety device market now exceeds $5 billion globally and is projected to grow to nearly $10 billion by 2033. [6] That investment has produced retractable needles, shielded syringes, safety IV catheters, and needleless systems - all of which were designed around hospital and clinic workflows.

None of them were designed for preclinical research.

The gap is structural, not incidental. Hospital safety devices assume large injection volumes, stable patients, sterile drape fields, and two-handed technique. In biosafety cabinets, glove boxes, and cage-side settings:

• Small syringes and fine-gauge needles required for rodent dosing are incompatible with most built-in safety mechanisms
• One-handed restraint makes two-handed safety activation physically impossible
• Standard retractable or shielded devices create workflow disruptions that lead technicians to bypass them entirely

The result is a setting with some of the highest needle volumes in healthcare-adjacent work, staffed by workers with injury rates rivaling clinical nurses, and equipped with safety tools that were never built for the environment.

Most preclinical research labs are running high-volume needle protocols with hospital-designed safety devices that don't fit their workflows - or no safety devices at all.

Engineering the Gap Closed

KODA Ideaworks developed HypoHolder to address exactly this problem.

HypoHolder is a Class I FDA-registered safety device that enables secure, one-handed uncapping, recapping, and temporary stabilization of hypodermic needles. Its stable, magnetically attachable base allows it to integrate into biosafety cabinets, cage-side setups, glove boxes, surgical fields, and clinical workstations without disrupting existing protocols or requiring retraining.

In preclinical and veterinary settings, where one hand is managing an animal and the other must handle the needle, HypoHolder provides the engineering control that makes safe one-handed technique possible. The needle is placed into the HypoHolder between animals. The cap is seated in a single motion. The hand never crosses the needle tip.

This is the specific failure mode - two-handed recapping under time pressure, with one hand occupied and an animal still in contact - that accounts for a disproportionate share of NSIs in research labs. HypoHolder addresses it directly.

It does not replace existing safety devices. It fills the procedural phase they leave unprotected.

Four Things Preclinical Research Programs Should Do Now

1. Count your injuries - including the ones that go unreported. Most labs are operating with incomplete NSI data. A formal baseline is the prerequisite for meaningful prevention. If your injury log looks light, it probably is.

2. Evaluate engineering controls against actual workflow conditions. The OSHA Bloodborne Pathogens Standard requires annual exposure control plan review. That review should include an honest assessment of whether the safety devices in your lab were designed for your procedures - or borrowed from a clinical setting where the workflow looks nothing like yours.

3. Treat recapping as the primary risk event it is. More than 25% of NSIs in research and veterinary settings involve recapping. If your lab requires needle recapping between animals - and most do - that moment needs an engineered solution, not a training reminder.

4. Frame sharps safety as a research integrity issue, not just an HR issue. When a trained technician is removed from a GLP study mid-protocol, the injury affects the data. Every preclinical research program has a scientific interest in preventing the NSIs that disrupt it.

The Problem Is Documented. The Solution Exists. The Gap Is Voluntary.

Preclinical research workers sustain needlestick injuries at rates the field has normalized but the data does not support accepting. The unique exposure profile of animal research - experimental compounds, manual restraint, constrained spaces, high-volume dosing - makes the risk profile distinct from clinical settings and, in several important respects, more severe.

The safety device market has addressed the hospital. It has not addressed the lab. That gap has been filled.

HypoHolder is available today for preclinical research, veterinary, surgical, and clinical environments. Facilities that have not yet evaluated it are carrying a preventable and quantifiable risk - to their personnel, their protocols, and their data.

Learn more at hypoholder.com

KODA Ideaworks develops safety-engineered needle handling solutions for surgical, clinical, dental, veterinary, and preclinical research environments.